{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A130", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004194, "timestamp_received": "2026-09-25T01:17:03.300632+00:00Z", "timestamp_returned": "2026-09-25T01:17:03.304826+00:00Z", "trace_id": "1ed4ad60-b738-418b-999a-c07de4b3c490" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:tarceva:0:1", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2016-10-18:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2016-10-18", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:tarceva", "type": "Document", "documentType": "Regulatory approval", "name": "Tarceva (erlotinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "OSI Pharmaceuticals, LLC.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tarceva", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "erlotinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 21743, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2016-10-18", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:130", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:NSCLC", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC" ] } }, "objectTherapeutic": { "id": "tx:ncit:C65530", "conceptType": "Therapy", "name": "Erlotinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:337525", "code": "337525", "name": "erlotinib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=337525" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4185613", "code": "4185613", "name": "Erlotinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4185613" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:414123001", "code": "414123001", "name": "Erlotinib", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=414123001&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1325363", "code": "1325363", "name": "erlotinib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1325363" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "EGFR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C65530", "code": "C65530", "name": "Erlotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:9", "present": true, "subject": { "id": "bmkr:9", "type": "CategoricalVariant", "name": "EGFR p.L858R", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "type": "Allele", "name": "NP_005219.2:p.Leu858Arg", "aliases": [ "NP_005219.2:p.L858R", "EGFR p.L858R" ], "description": "VRS variation of NP_005219.2:p.Leu858Arg", "digest": "S41CcMJT2bcd8R4-qXZWH1PoHWNtG2PZ", "expressions": [ { "syntax": "hgvs.p", "value": "NP_005219.2:p.Leu858Arg", "extensions": [ { "name": "hgvs.p_short", "value": "p.L858R" } ] } ], "location": { "id": "ga4gh:SL.v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 858 of the Refseq protein NP_005219.2, which is the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5).", "digest": "v0_edynH98OIu-0QPVT5anCSOriAFSDQ", "sequenceReference": { "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "type": "SequenceReference", "name": "NP_005219.2", "aliases": [ "ensembl:ENSP00000275493.2", "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "refseq:NP_005219.2" ], "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.", "moleculeType": "protein", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "residueAlphabet": "aa" }, "start": 857, "end": 858, "sequence": "L" }, "state": { "type": "LiteralSequenceExpression", "sequence": "R" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3236", "conceptType": "Gene", "name": "EGFR", "primaryCoding": { "id": "coding:hgnc:3236", "code": "HGNC:3236", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000146648", "code": "ENSG00000146648", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000146648" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:1956", "code": "1956", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/1956" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005228.5", "code": "NM_005228.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": 55259515 }, { "name": "end_position", "value": 55259515 }, { "name": "reference_allele", "value": "T" }, { "name": "alternate_allele", "value": "G" }, { "name": "cdna_change", "value": "c.2573T>G" }, { "name": "protein_change", "value": "p.L858R" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 21 }, { "name": "rsid", "value": "rs121434568" }, { "name": "hgvsg", "value": "7:g.55259515T>G" }, { "name": "hgvsc", "value": "ENST00000275493.2:c.2573T>G" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:tarceva:0", "type": "Indication", "description": "TARCEVA is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. TARCEVA is not recommended for use in combination with platinum-based chemotherapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2016-10-18:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2016-10-18", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:tarceva", "type": "Document", "documentType": "Regulatory approval", "name": "Tarceva (erlotinib) [package insert]. FDA.", "title": null, "aliases": [], "description": "OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "OSI Pharmaceuticals, LLC.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tarceva", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "erlotinib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 21743, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2016-10-18", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }